ClinicalTrials.gg
RecruitingNCT07383506Updated Oct 22, 2026

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

A Phase 1 interventional study of CGT6297 in PIK3CA Mutations, Advanced Solid Tumors, Adult and Endometrial Cancer, sponsored by Cogent Biosciences, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cogent Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 22, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 286 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
231st of 591
90 · median 60
Started
2026
with 45 others
Phase 1
192 of 715
50 open now
Primary completion
2029-07
later than 246 of 285 live
Registered
680th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 231st largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 192 in phase 1, reaches primary completion later than 246 of the 285 other live ones, and was the 680th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

191 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations

03

Conditions studied

  • PIK3CA Mutations
  • Advanced Solid Tumors, Adult
  • Endometrial Cancer
  • HR Positive/HER-2 Negative Breast Cancer
  • HER2-low Breast Cancer

Keywords

  • HER2
  • PI3K
  • Mutant-Selective Inhibitor
  • Advanced solid tumors
  • PIK3CA Mutations
  • PIK3CA SNVs
  • Endometrial Cancer
  • Breast Cancer
  • HR+/HER2 Negative breast cancer
  • HR+/HER2 (-) breast cancer
  • HR+/HER2 low breast cancer
  • PI3KCA Genetic Alterations
  • PI3KCA Point Mutations
  • PI3KCA Gene Short Variants
  • PI3KCA active alteration
  • HER2-low Breast Cancer
  • Phase 1a/1b
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed advanced solid tumor harboring oncogenic PIK3CA mutations in blood and/or tumor:

    1. Phase 1b Cohort 1, participants must have PIK3CA endometrial cancer
    2. Phase 1b Cohort 2, participants must have HR-positive/-negative or HER2-low breast cancer (immunohistochemistry [IHC] and in-situ hybridization results must meet ASCO-College of American Pathology guidelines for breast cancer or criteria)
    3. Phase 1b Cohort 3 will allow all solid tumors that do not meet criteria for Phase 1b Cohorts 1 or 2, including head and neck cancers, other gynecological cancers, colorectal cancers harboring PIK3CA mutations
  2. Meet prior treatment requirement of:

    1. Phase 1a: previously treated with and to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.
    2. Phase 1b: previously treated with or considered not appropriate for SOC treatment for their condition
  3. Have at least one according to v1.1.
  4. (ECOG) Performance Status 0 to 1
  5. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
  6. Resolution of acute toxicities from prior anticancer therapy to ≤Grade 1 (or baseline), including resolution of laboratory abnormalities (other than parameters specified in screening testing as outlined below), as determined by the National Cancer Institute- (NCICTCAE) v5.0.
  7. Have an ≥50%

Exclusion criteria

Exclusion Criteria:

  1. Received small molecule chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.
  2. Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug
  3. Treatment with radiotherapy ≤2 weeks before the first dose of study drug.
  4. cardiac disease
  5. Ongoing or planned long-term (≥4 consecutive weeks) treatment with steroids at greater than physiologic dosing (defined as equivalent to >20 mg/day prednisone)
  6. Diagnosis of diabetes mellitus type 1 or uncontrolled diabetes mellitus type 2 (defined as fasting glucose ≥140 mg/dL and ≥7.0%; antihyperglycemic medical management permitted with the exception of insulin)
  7. Previous molecular testing (NGS or PCR) showed tumor with the following mutations: mutations/deletions in PTEN or activating mutations in AKT, HRAS/KRAS/NRAS, EGFR, and BRAF
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Part 1a: Dose Escalation of Multiple doses of CGT6297 for oral administration

    Drug: CGT6297

  • Experimental
    Signal Seeking

    Phase 1b: Participants will receive CGT6297 at a dose level selected based on data from Phase 1a

    Drug: CGT6297

Interventions

  • DrugCGT6297

    CGT6297 Daily Oral Administration

06

What researchers measure

Primary outcomes

  1. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a]

    Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) and AEs leading to dose modifications and dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD) or the maximum evaluated dose (MED) of CGT6297 in participants with advanced solid tumors harboring PIK3CA mutations

    Time frame: Approximately 12 months

  2. Overall Response Rate [Phase 1b]

    Overall Response Rate (ORR), as determined by CR + PR based on Investigator assessment using RECIST v1.1

    Time frame: Approximately 8 months

Secondary outcomes

  1. Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1b]

    * Incidence and grade of Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs leading to dose modification * Changes from baseline in key laboratory results and electrocardiogram (ECG) parameters

    Time frame: Approximately 12 months

  2. Pharmacokinetics (Part 1a)

    Area under the concentration-time curve (AUC) in participants with advanced solid tumors harboring PI3K mutations

    Time frame: Approximately 28 days

  3. Pharmacokinetics (Part 1a)

    Maximum observed concentration (Cmax) in participants with advanced solid tumors harboring PI3K mutations

    Time frame: Approximately 28 days

  4. Pharmacokinetics (Part 1a)

    Observed concentration at predose (Ctrough) in participants with advanced solid tumors harboring PI3K mutations

    Time frame: Approximately 28 days

  5. Pharmacokinetics (Part 1a)

    Time to maximum concentration (Tmax) in participants with advanced solid tumors harboring PI3K mutations

    Time frame: Approximately 28 days

  6. Disease Response (Part 1b)

    Objective response rate (ORR), determined by confirmed (CR) + (PR) based on Investigator assessment using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: Approximately 8 months

  7. Disease Response (Part 1b)

    Disease control rate (DCR), as determined by confirmed CR + PR + stable disease (SD) based on Investigator assessment using RECIST v1.1

    Time frame: Approximately 28 days

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 36 months is below that.

Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Jul 23, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Aug 2029
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Stanford Cancer Center · Palo Alto, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    1 site added
    Show site
    • Stanford Cancer Center · Palo Alto, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07383506
Lead sponsor
Cogent Biosciences, Inc.
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Jul 23, 2026
Primary completion
Jul 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

Cogent Biosciences, Inc
Contact
trialinfo@cogentbio.com
6179455576

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion